| EVOLOCUMAB | Antibody | coronary artery disease | Subtilisin/kexin type 9 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| ALIROCUMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | homozygous familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 2.0 | Completed | ClinicalTrials |
| ALIROCUMAB | Antibody | peripheral arterial disease | Subtilisin/kexin type 9 inhibitor | 4.0 | Active, not recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | homozygous familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| TAFOLECIMAB | Antibody | familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | cardiovascular disease | Subtilisin/kexin type 9 inhibitor | 2.0 | Completed | ClinicalTrials |
| INCLISIRAN | Oligonucleotide | cardiovascular disease | PCSK9 mRNA RNAi inhibitor | 3.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | carotid artery disease | Subtilisin/kexin type 9 inhibitor | 4.0 | Recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | acute coronary syndrome | Subtilisin/kexin type 9 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | hyperlipidemia | Subtilisin/kexin type 9 inhibitor | 2.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | stroke | Subtilisin/kexin type 9 inhibitor | 4.0 | - | DailyMed |
| EVOLOCUMAB | Antibody | acute coronary syndrome | Subtilisin/kexin type 9 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| BOCOCIZUMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 1.0 | Completed | ClinicalTrials |
| RALPANCIZUMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 1.0 | Completed | ClinicalTrials |
| INCLISIRAN | Oligonucleotide | hyperlipidemia | PCSK9 mRNA RNAi inhibitor | 1.0 | Completed | ClinicalTrials |
| INCLISIRAN | Oligonucleotide | Hypercholesterolemia | PCSK9 mRNA RNAi inhibitor | 4.0 | Recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | coronary artery disease | Subtilisin/kexin type 9 inhibitor | 4.0 | Withdrawn | ClinicalTrials |
| EVOLOCUMAB | Antibody | coronary artery disease | Subtilisin/kexin type 9 inhibitor | 4.0 | Recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | cerebral atherosclerosis | Subtilisin/kexin type 9 inhibitor | 4.0 | Not yet recruiting | ClinicalTrials |
| ONGERICIMAB | Antibody | cancer | Subtilisin/kexin type 9 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| LERODALCIBEP | Protein | cardiovascular disease | Subtilisin/kexin type 9 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | hyperlipidemia | Subtilisin/kexin type 9 inhibitor | 4.0 | Recruiting | ClinicalTrials |
| ALIROCUMAB | Antibody | cardiovascular disease | Subtilisin/kexin type 9 inhibitor | 4.0 | - | ATC |
| INCLISIRAN | Oligonucleotide | cardiovascular disease | PCSK9 mRNA RNAi inhibitor | 3.0 | Recruiting | ClinicalTrials |
| BOCOCIZUMAB | Antibody | familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| ONGERICIMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 1.0 | Completed | ClinicalTrials |
| ALIROCUMAB | Antibody | familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 4.0 | Terminated | ClinicalTrials |
| ONGERICIMAB | Antibody | hyperlipidemia | Subtilisin/kexin type 9 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | COVID-19 | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | ST Elevation Myocardial Infarction | Subtilisin/kexin type 9 inhibitor | 4.0 | Not yet recruiting | ClinicalTrials |
| FROVOCIMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 1.0 | Completed | ClinicalTrials |
| INCLISIRAN SODIUM | Oligonucleotide | atherosclerosis | PCSK9 mRNA rnai inhibitor | 4.0 | - | FDA |
| EVOLOCUMAB | Antibody | non-small cell lung carcinoma | Subtilisin/kexin type 9 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| BOCOCIZUMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 2.0 | Completed | ClinicalTrials |
| TAFOLECIMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 2.0 | Unknown status | ClinicalTrials |
| EVOLOCUMAB | Antibody | glioblastoma multiforme | Subtilisin/kexin type 9 inhibitor | 0.5 | Recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | heart failure | Subtilisin/kexin type 9 inhibitor | 2.0 | Completed | ClinicalTrials |
| ALIROCUMAB | Antibody | familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| INCLISIRAN | Oligonucleotide | acute coronary syndrome | PCSK9 mRNA RNAi inhibitor | 3.0 | Recruiting | ClinicalTrials |
| INCLISIRAN | Oligonucleotide | homozygous familial hypercholesterolemia | PCSK9 mRNA RNAi inhibitor | 2.0 | Completed | ClinicalTrials |
| ALIROCUMAB | Antibody | acute myocardial infarction | Subtilisin/kexin type 9 inhibitor | 4.0 | Recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | hyperlipidemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | homozygous familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 4.0 | Completed | ClinicalTrials |
| ALIROCUMAB | Antibody | coronary artery disease | Subtilisin/kexin type 9 inhibitor | 4.0 | Recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | cardiovascular disease | Subtilisin/kexin type 9 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| ALIROCUMAB | Antibody | familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 4.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 2.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | myocardial infarction | Subtilisin/kexin type 9 inhibitor | 4.0 | - | DailyMed |
| EVOLOCUMAB | Antibody | Ischemic stroke | Subtilisin/kexin type 9 inhibitor | 4.0 | Withdrawn | ClinicalTrials |
| EVOLOCUMAB | Antibody | peripheral arterial disease | Subtilisin/kexin type 9 inhibitor | 4.0 | Recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | acute coronary syndrome | Subtilisin/kexin type 9 inhibitor | 4.0 | Recruiting | ClinicalTrials |
| TAFOLECIMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 1.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | cardiovascular disease | Subtilisin/kexin type 9 inhibitor | 4.0 | - | DailyMed,ATC |
| BOCOCIZUMAB | Antibody | hyperlipidemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 4.0 | Terminated | ClinicalTrials |
| ONGERICIMAB | Antibody | hyperlipidemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | ST Elevation Myocardial Infarction | Subtilisin/kexin type 9 inhibitor | 4.0 | Recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | hyperlipoproteinemia type 3 | Subtilisin/kexin type 9 inhibitor | 4.0 | Unknown status | ClinicalTrials |
| ONGERICIMAB | Antibody | familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| ALIROCUMAB | Antibody | coronary artery disease | Subtilisin/kexin type 9 inhibitor | 4.0 | - | DailyMed |
| EVOLOCUMAB | Antibody | type 2 diabetes mellitus | Subtilisin/kexin type 9 inhibitor | 4.0 | Completed | ClinicalTrials |
| ALIROCUMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 1.0 | Completed | ClinicalTrials |
| INCLISIRAN | Oligonucleotide | familial hypercholesterolemia | PCSK9 mRNA RNAi inhibitor | 3.0 | Completed | ClinicalTrials |
| LERODALCIBEP | Protein | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| INCLISIRAN | Oligonucleotide | cardiovascular disease | PCSK9 mRNA RNAi inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| BOCOCIZUMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 1.0 | Terminated | ClinicalTrials |
| EVOLOCUMAB | Antibody | Sepsis | Subtilisin/kexin type 9 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| ALIROCUMAB | Antibody | atherosclerosis | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | chronic kidney disease | Subtilisin/kexin type 9 inhibitor | 4.0 | Withdrawn | ClinicalTrials |
| EVOLOCUMAB | Antibody | ST Elevation Myocardial Infarction | Subtilisin/kexin type 9 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| ALIROCUMAB | Antibody | non-small cell lung carcinoma | Subtilisin/kexin type 9 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| TAFOLECIMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| ALIROCUMAB | Antibody | inflammation | Subtilisin/kexin type 9 inhibitor | 4.0 | Withdrawn | ClinicalTrials |
| ALIROCUMAB | Antibody | Sepsis | Subtilisin/kexin type 9 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| ALIROCUMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 2.0 | Completed | ClinicalTrials |
| LERODALCIBEP | Protein | familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | hyperlipidemia | Subtilisin/kexin type 9 inhibitor | 1.0 | Completed | ClinicalTrials |
| LERODALCIBEP | Protein | homozygous familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | acute coronary syndrome | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| ALIROCUMAB | Antibody | familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 4.0 | - | DailyMed |
| ALIROCUMAB | Antibody | familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 2.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | inflammation | Subtilisin/kexin type 9 inhibitor | 4.0 | Withdrawn | ClinicalTrials |
| ALIROCUMAB | Antibody | cardiovascular disease | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| ALIROCUMAB | Antibody | nephrotic syndrome | Subtilisin/kexin type 9 inhibitor | 2.0 | Terminated | ClinicalTrials |
| INCLISIRAN | Oligonucleotide | Hypercholesterolemia | PCSK9 mRNA RNAi inhibitor | 1.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | ischemia | Subtilisin/kexin type 9 inhibitor | 4.0 | Recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 2.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | cardiovascular disease | Subtilisin/kexin type 9 inhibitor | 4.0 | Completed | ClinicalTrials |
| ALIROCUMAB | Antibody | Disorder of lipid metabolism | Subtilisin/kexin type 9 inhibitor | 2.0 | Completed | ClinicalTrials |
| INCLISIRAN | Oligonucleotide | familial hypercholesterolemia | PCSK9 mRNA RNAi inhibitor | 3.0 | Recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | lung cancer | Subtilisin/kexin type 9 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | Ischemic stroke | Subtilisin/kexin type 9 inhibitor | 4.0 | Terminated | ClinicalTrials |
| FROVOCIMAB | Antibody | hyperlipidemia | Subtilisin/kexin type 9 inhibitor | 1.0 | Completed | ClinicalTrials |
| ALIROCUMAB | Antibody | Disorder of lipid metabolism | Subtilisin/kexin type 9 inhibitor | 4.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | Combined hyperlipidemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| ONGERICIMAB | Antibody | Combined hyperlipidemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | Non-ST Elevation Myocardial Infarction | Subtilisin/kexin type 9 inhibitor | 4.0 | Recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | internal carotid artery stenosis | Subtilisin/kexin type 9 inhibitor | 4.0 | Active, not recruiting | ClinicalTrials |
| ALIROCUMAB | Antibody | Disorder of lipid metabolism | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| INCLISIRAN | Oligonucleotide | homozygous familial hypercholesterolemia | PCSK9 mRNA RNAi inhibitor | 3.0 | Completed | ClinicalTrials |
| ALIROCUMAB | Antibody | homozygous familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| ALIROCUMAB | Antibody | diabetes mellitus | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | atherosclerosis | Subtilisin/kexin type 9 inhibitor | 4.0 | Recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | Disorder of lipid metabolism | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| ALIROCUMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 4.0 | Completed | ClinicalTrials |
| FROVOCIMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 2.0 | Completed | ClinicalTrials |
| BOCOCIZUMAB | Antibody | cardiovascular disease | Subtilisin/kexin type 9 inhibitor | 3.0 | Terminated | ClinicalTrials |
| ONGERICIMAB | Antibody | hyperlipidemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| INCLISIRAN SODIUM | Oligonucleotide | familial hypercholesterolemia | PCSK9 mRNA rnai inhibitor | 4.0 | - | FDA |
| INCLISIRAN | Oligonucleotide | kidney disease | PCSK9 mRNA RNAi inhibitor | 1.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| TAFOLECIMAB | Antibody | homozygous familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | coronary artery disease | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | coronary artery disease | Subtilisin/kexin type 9 inhibitor | 4.0 | - | DailyMed |
| EVOLOCUMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Completed | ClinicalTrials |
| EVOLOCUMAB | Antibody | familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 4.0 | - | DailyMed |
| TAFOLECIMAB | Antibody | Hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| EVOLOCUMAB | Antibody | Reduced left ventricular ejection fraction | Subtilisin/kexin type 9 inhibitor | 2.0 | Completed | ClinicalTrials |
| INCLISIRAN | Oligonucleotide | Hypercholesterolemia | PCSK9 mRNA RNAi inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| INCLISIRAN | Oligonucleotide | cardiovascular disease | PCSK9 mRNA RNAi inhibitor | 4.0 | - | ATC |
| INCLISIRAN | Oligonucleotide | coronary artery disease | PCSK9 mRNA RNAi inhibitor | 3.0 | Recruiting | ClinicalTrials |
| ALIROCUMAB | Antibody | atherosclerosis | Subtilisin/kexin type 9 inhibitor | 4.0 | Terminated | ClinicalTrials |
| TAFOLECIMAB | Antibody | familial hypercholesterolemia | Subtilisin/kexin type 9 inhibitor | 2.0 | Recruiting | ClinicalTrials |